Average Ratings 0 Ratings

Total 0 out of 5 stars
ease 0 out of 5 stars
features 0 out of 5 stars
design 0 out of 5 stars
support 0 out of 5 stars

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total 0 out of 5 stars
ease 0 out of 5 stars
features 0 out of 5 stars
design 0 out of 5 stars
support 0 out of 5 stars

No User Reviews. Be the first to provide a review:

Write a Review

Description

We combine clinical and experimental data through machine learning techniques to explore human disease biology and promote the development of precision medicine. Our innovative Contingent AI™ technology comprehends the intricate relationships present in the data, yielding advanced insights. To combat data bias, we refine our machine learning models based on decisions made during the pre-processing and feature engineering phases. We utilize zebrafish, cellular, and various phenotypic animal models to test and confirm in silico predictions through in vivo experiments, along with genetic modifications conducted both in vitro and in vivo to enhance translation. By employing active learning and computer vision on validated models that focus on cardiac, central nervous system, and rare disorders, we swiftly integrate new data into our machine learning frameworks, allowing for continuous improvement and adaptation in our methodologies. This iterative process not only enhances the accuracy of our predictions but also enables us to stay at the forefront of research in precision medicine.

Description

Healthcare providers and pharmaceutical firms leverage RetinAI's software platform to effectively manage their data while benefiting from enhanced insights through automated AI analysis, thereby optimizing both clinical and research workflows. This unified data platform allows users to access and manage their information from any location at any time. It supports a variety of formats, including DICOM-compliant and proprietary types. By utilizing AI, data is harmonized, organized, aggregated, and analyzed on a large scale to uncover insights related to disease progression, treatment outcomes, and predictions of disease advancement. Additionally, the platform facilitates collaborative research within organizations by providing secure cloud-based access to data. It serves as a central hub for data, medical, and digital teams. Users can conduct AI-driven analysis on their OCT volumes, focusing on layer and fluid segmentation. Immediate evaluations can be performed to consolidate insights into a single platform. Collaborators can be swiftly invited to access and interact with datasets according to specified permission levels, fostering a more integrated research environment. This comprehensive approach not only streamlines data management but also enhances collaborative efforts across different teams and disciplines.

API Access

Has API No 

API Access

Has API No 

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

No price information available.
Free Trial No 
Free Version No 

Pricing Details

No price information available.
Free Trial No 
Free Version No 

Deployment

Web-Based Yes 
On-Premises No 
iPhone App No 
iPad App No 
Android App No 
Windows No 
Mac No 
Linux No 
Chromebook No 

Deployment

Web-Based Yes 
On-Premises No 
iPhone App No 
iPad App No 
Android App No 
Windows No 
Mac No 
Linux No 
Chromebook No 

Customer Support

Business Hours No 
Live Rep (24/7) No 
Online Support Yes 

Customer Support

Business Hours No 
Live Rep (24/7) Yes 
Online Support Yes 

Types of Training

Training Docs No 
Webinars No 
Live Training (Online) No 
In Person No 

Types of Training

Training Docs Yes 
Webinars Yes 
Live Training (Online) Yes 
In Person Yes 

Vendor Details

Company Name

BioSymetrics

Country

United States

Website

www.biosymetrics.com/platform

Vendor Details

Company Name

RetinAI

Country

Switzerland

Website

www.retinai.com

Product Features

Alternatives

Alternatives

StarDrop Reviews

StarDrop

Optibrium
AIDDISON Reviews

AIDDISON

Merck KGaA